The pharmaceutical sector has never been in the limelight in such a conjoined, simultaneous, worldwide capacity before. Coronavirus has posed a whole new problem; the industry is at a halt in terms of developing a vaccine and must mobilize faster than ever before, despite specific constraints and hurdles. The industry's capacity to explain the changes, difficulties, and possibilities it presents in different languages is almost as challenging as developing a vaccine. However, because the supply chain had been disrupted, the supply of essential healthcare products began to dwindle at an alarming rate. As a result of the emergence of COVID-19, this industry has become one of the busiest sectors in the world.